Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Proxy advisory firm Glass Lewis backs Bergeron in Ethan Allen fight

Proxy advisory firm Glass Lewis backs Bergeron in Ethan Allen fight

Proxy advisory firm Glass Lewis endorsed Doug Bergeron's bid to replace all five directors at Ethan Allen, including the company's 82-year-old CEO, Farooq Kathwari. Bergeron and his investment firm, DGB Investments, control 5.2% of the $515 million company, renowned for colonial wood revival furniture and U.S. diplomatic home decor.

Glass Lewis joined Egan-Jones Proxy Services in recommending investors cast ballots for all of Bergeron's director candidates. The activist investor contends that his slate of executives with backgrounds in home furnishings, turnarounds, luxury retail, and digital strategy can restore profitable growth and triple shareholder value within three years.

Ethan Allen's stock has dropped over a quarter of its value in the past year, closing Friday at $20.45. The company's incumbent management and board have overseen continuous structural decline and a risky capital program. Ethan Allen aims to appoint a successor to Kathwari by June 30, 2027, though Kathwari will stay on as CEO during the search and until the 2027 annual meeting. Ethan Allen has not commented on the Glass Lewis recommendation.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Read the original at investing.com →

More in Finance & Markets

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?

Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.

  • Bristol Myers Squibb trades at 9.7 times forward earnings, below the five-year average
  • Competitor Eli Lilly has a much higher forward earnings ratio of 35.6 times
  • Bristol Myers Squibb's lower valuation stems from upcoming patent expirations on Opdivo and Eliquis

Crypto market unfazed by protests

Protests spreading across Europe have had limited impact on Bitcoin thus far, but if the unrest turns into a wider European bond or equity sell-off, it could weigh on risk appetite across assets…

More from Sunday 25 October →